Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy

NCT07670962 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Ovarian Cancer

Interventions

DIAGNOSTIC_TEST: Blood-based ctDNA minimal residual disease (MRD) test

Sponsor

Asan Medical Center